Comparison of Anti-Microbic and Anti-Biofilm Activity Among Tedizolid and Radezolid Against Linezolid-Resistant *Enterococcus faecalis* Isolates

Lingbo Wang^{1,*}Ying Zhang^{2,*}Shixing Liu¹Na Huang¹Weiliang Zeng¹Wenya Xu¹Tieli Zhou¹Mo Shen¹

¹Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China;

²School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China

*These authors contributed equally to this work

Background: The emergence and spread of linezolid-resistant *Enterococcus faecalis* (*E. faecalis*) have emerged as a serious threat to human health globally. Therefore, this study aims to compare the anti-microbic as well as the anti-biofilm activity of linezolid, tedizolid, and radezolid against linezolid-resistant *E. faecalis*.

Methods: A total of 2128 *E. faecalis* isolates were assessed from the First Affiliated Hospital of Wenzhou Medical University from 2011 to 2019. Antibiotic sensitivity was evaluated using the micro broth dilution method. Oxazolidinone-resistant chromosomal and plasmid-borne genes such as *cfr*, *cfr(A)*, *cfr(B)*, *cfr(C)*, *cfr(D)*, *optrA*, and *poxA* were detected by PCR and then sequenced to detect the presence of mutations in the domain V of the 23S rRNA and the ribosomal proteins L3, L4, and L22. Conjugation experiments were conducted using the broth method. The inhibition and eradication of biofilm were evaluated through crystal violet staining, whereas the efflux pump activities were detected by agar dilution.

Results: Out of 2128 isolated *E. faecalis*, 71 (3.34%) were linezolid-resistant isolates in which the MICs of tedizolid and radezolid ranged from 1 to 4 µg/mL and 0.5–1 µg/mL, respectively. The MIC₅₀/MIC₉₀ of tedizolid and radezolid were 4 and 8-fold lower than the linezolid, respectively. Out of 71 resistant isolates, 57 (80.28%) carried *optrA*, 1 (1.41%) carried *cfr*, 4 (5.63%) carried *optrA* and *cfr*, and 6 (8.45%) carried *optrA* and *cfr(D)*, with no mutations of 23S rRNA gene and ribosomal proteins L3, L4, and L22. Besides, the transfer rate of the *optrA*, *cfr*, and *cfr(D)* was 17.91%, 0% and 0%, respectively. Radezolid showed more effectiveness in eradicating biofilm (8 × MIC). However, tedizolid was more effective than radezolid and linezolid in inhibiting the biofilm formation (1/4 MIC, 1/8MIC, and 1/16MIC). Additionally, in combination with CCCP, the MICs of radezolid in all linezolid-resistant isolates decreased ≥4-fold.

Conclusion: Radezolid showed greater antimicrobial activity than tedizolid and linezolid against linezolid-resistant *E. faecalis*. However, both tedizolid and radezolid showed differential activity on biofilm inhibition, eradication, and efflux pump compared to linezolid. Thus, our study might bring important clinical value in the application of these drugs for resistant pathogenic strains.

Keywords: *Enterococcus faecalis*, linezolid, tedizolid, radezolid, in vitro activity, anti-biofilm activity

Correspondence: Mo Shen; Tieli Zhou
Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China
Tel +86-577-8668-9885
Email shenmo601@163.com; wytli@163.com

Introduction

Enterococcus is a Gram-positive bacteria organism that is the most common hospital-acquired infection.¹ It is a significant public concern globally due to substantial morbidity and mortality worldwide.² *Enterococcus faecalis* (*E. faecalis*) is a pathogenic strain and accounts for approximately 97% of all

infective endocarditis (IE) cases, as a hospital acquired infection.³ In recent years, multidrug-resistant (MDR) *E. faecalis* has spread rapidly with its high ability to form biofilm. Unfortunately, the MDR infections caused by *E. faecalis* are hard to cure, making the clinical treatment ever challenging. Besides, the choices for anti-infective therapies are further narrowed due to the intrinsic and acquired resistance of *E. faecalis*.⁴ The limited availability of novel antimicrobial agents is also posing difficulties for anti-infection treatment in clinics. Thus, new effective ways for the treatment of MDR *E. faecalis* infection are urgently warranted.

Oxazolidinone is a new class of antibacterial agents that inhibits bacterial protein synthesis by preventing the binding of the aminoacyl-tRNA to the site of the ribosome.^{5–7} Linezolid was the first clinically helpful oxazolidinone antibacterial agent approved by the US Food and Drug Administration (FDA).⁸ However, linezolid-resistant *Staphylococcus aureus* and *Enterococcus spp* emergence have risen in recent years due to the extensive use of linezolid in clinical practice.⁹ Therefore, it is extremely important to develop new oxazolidinone antimicrobial agents.

Tedizolid, a novel oxazolidinone prodrug, is the second-generation oxazolidinone approved by the FDA (Food and Drug Administration). It exerts its antibacterial activity by binding to the peptidyl transferase center (PTC) of the 50S subunit of the bacterial ribosome, making it more active against *enterococci* than linezolid.¹⁰ Moreover, structural differences between the C- and D-loop creates additional target site for interaction with 23S rRNA residues to form the PTC binding site, enhancing the effectiveness of tedizolid.¹¹ Radezolid is another oxazolidinone antimicrobial agent possessing enhanced antibacterial potency against antibiotic-resistant Gram-positive bacteria compared with linezolid. It exerts its antimicrobial activity by forming π - π stacking interactions with the 50S subunit of the bacteria.¹² Till now, only a few studies have compared the antibacterial activity of tedizolid and radezolid with linezolid against the *Staphylococcus aureus* and *Enterococcus*.^{13,14} However, the comparison of in vitro activity of these two oxazolidinone agents against linezolid-resistant *E. faecalis* remains unknown.

Linezolid resistance is unusual among enterococci, however, the number of linezolid-resistant strains has increased gradually over the years. The resistance in enterococci is generally contributed by the point mutations in the chromosomal 23S rRNA gene, although the amino

acid change G2576T being the predominant one, other changes (G2505A, U2500A, G2447U, C2534U, and G2603U) have also been reported;¹⁵ Mutations in the ribosomal proteins L3, L4, and L22 encoded by *rplC*, *rplD*, and *rplV* genes contributed to linezolid resistance.¹⁶ On the other hand, the acquisition of the plasmid-borne genes (*cfr*, *cfr(B)*, *cfr(D)*, *optrA*, and *poxtA*) can also cause resistance from linezolid.^{17,18} The *cfr* gene and its variants *cfr(B)* and *cfr(D)* have also been reported in the resistance to oxazolidinones. This encodes for rRNA methyltransferase, which modifies the adenine residue at the 2503 position of domain V in the 23S rRNA.¹⁹ The *optrA* gene encodes the ATP-binding cassette F (ABC-F) protein and mediates resistance to oxazolidinones by protecting the bacterial ribosome. *PoxtA* is another gene associated with decreased susceptibility to oxazolidinones.¹⁷ Tedizolid possesses greater in-vitro potency than its first-class predecessor, linezolid. The G2576T mutation²⁰ are known to generate resistance against tedizolid, and the presence of *optrA*²¹ are known to generate resistance against tedizolid. Although fewer studies report the resistance to radezolid, it is related to the mutations in the V domain of 23S rRNA.²² Biofilms are enclosed exopolymer matrix on bacteria, restricting the diffusion as well as the penetration of antimicrobials. Although biofilms structure reduces the antibacterial effect, linezolid has been reported to have good inhibitory effects on *E. faecalis* biofilms,^{23,24} which may be related to the time and dosage of treatment and the inhibition of the number of bacteria in the growing biofilm.²⁵ Besides, previous research has reported that the MICs for linezolid or radezolid showed a 2 to 8 fold decreased by the presence of PA β N (efflux pump inhibitors).²⁶ Although tedizolid and radezolid belong to the same oxazolidinones class drugs, the differences in their antimicrobial activity against linezolid-resistant *E. faecalis* are still unclear. Moreover, the variable effect of tedizolid and radezolid on the biofilm of linezolid-resistant *E. faecalis* compared with linezolid and the role and differences of efflux pump in these three generations oxazolidinones resistance is still largely unknown.

Therefore, the current study was carried out to understand and compare the antimicrobial as well as the anti-biofilm activity among linezolid, tedizolid, and radezolid against linezolid-resistant clinical *E. faecalis*. Further, the differences in the effect of biofilm and efflux pump inhibitors among three antimicrobial agents were also assessed. The result of this study is expected to make an

essential contribution to the control of hospital-acquired infections caused by the epidemic of *E. faecalis*.

Materials and Methods

Bacterial Strains and Antimicrobial Susceptibility Testing

During the year 2011–2019 period, 2128 clinical *E. faecalis* isolates were collected from the First Affiliated Hospital of Wenzhou Medical University, China. Identification of the isolates were performed by the matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS; bioMérieux, Lyons, France). In addition, duplicate strains isolated from the same part of the same patient were removed during strains collection. Minimum inhibitory concentrations (MICs) of linezolid, tedizolid and radezolid were determined by the microdilution broth method with cation-adjusted Mueller–Hinton broth based on the Clinical and Laboratory Standards Institute (CLSI, 2020),²⁷ whereas the *E. faecalis* ATCC 29212 was used for the quality control strain.

Detection of Linezolid Resistance Genes

The DNA of linezolid-resistant *E. faecalis* isolates were extracted using a Bioflux bacterial DNA Extraction Kit. The 23S rRNA and ribosomal proteins L3, L4, and L22 were amplified by the polymerase chain reaction (PCR) using the specific primers²⁸ (Table S1). The amplified PCR products were sequenced by Shanghai Majorbio Bio-Pharm Technology Co. (Shanghai, China). Further, the sequences were aligned to analyze any possible gene mutations by BLAST on the National Center for Biotechnology Information (NCBI) (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). The transferable resistance genes *cfr*, *cfr(A)*, *cfr(B)*, *cfr(C)*, *cfr(D)*, *optrA* and *potxA* were also screened by PCR assays using the primers²⁹ listed in Table S1.

Conjugation Experiments

Filter mating was conducted for the *cfr*-, *cfr(D)*- and *optrA*-positive strains of *E. faecalis* JH2-2 as recipients, based on the previously reported method.³⁰ Thereafter, the transconjugants were selected on Mueller–Hinton agar plates supplemented with 10 µg/mL florfenicol and 25 µg/mL rifampicin. The transconjugants were further confirmed by PCR.

Biofilm Biomass Assay

The inhibition and eradication of biofilm by linezolid, tedizolid or, radezolid against the 8 *E. faecalis* clinical isolates

(FC1996, FC2021, FC2234, FC2257, FC2279, FC2309, FC2471, FC2484) were performed. The crystal violet staining detected isolates were randomly selected as previously described.³¹ For biofilm eradication assay, *E. faecalis* strains were inoculated into 96-well polystyrene microtiter plates with Luria-Bertani broth (1% NaCl, 1% tryptone, 0.5% yeast extract) for the formation of mature biofilms. After 24 h of static incubation, the supernatants were discarded, and the plates were washed with 0.9% saline to remove unattached cells. Thereafter, fresh Luria-Bertani broth containing linezolid, tedizolid or radezolid (8 × MIC) was added to the wells. Till the 48 h of static incubation, the medium was replaced daily, and at the end of incubation the remaining biofilm biomass was determined by crystal violet staining. The biofilms biomass formed in 96-well polystyrene microtiter plates was determined by detecting the absorbance at 595nm. Additionally, the inhibition of *E. faecalis* biofilm formation by linezolid, tedizolid, or radezolid were also investigated based on the previous study.³² Briefly, the *E. faecalis* isolates were inoculated into 96-well polystyrene microtiter plates with Luria-Bertani broth containing linezolid, tedizolid or radezolid (at 1/4MIC, 1/8MIC, 1/16MIC). After 24 h of static incubation, the biofilm biomass was determined by the crystal violet staining. Each assay was performed in triplicate for at least three times.

Effect of Efflux Pump Inhibitor

The efflux pump activities in linezolid-resistant isolates were detected by using the efflux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP). The MICs for linezolid, tedizolid, and radezolid were determined in the presence or absence of the CCCP (10 µg/mL). Wherever the MIC of the strain decreased ≥4-fold after supplementing efflux pump inhibitor, the phenotype test regarded as positive.

RT-qPCR to Determine the Expressive Levels of *E. faecalis* Efflux Pump-Related Genes

The expression levels of *E. faecalis* (FC2234 FC2559 FC1728 FC1037 FC2398 FC2471) efflux pump-related genes (*OG1RF12220*, *OG1RF10126*, and *OG1RF10495*) were determined by RT-qPCR based on published reports.²⁶ Real-time qPCR was performed using the 7500 RT-PCR System (Thermo Fisher Scientific, Marsiling, Singapore) equipped with the SYBR Green RT-PCR Kit (TOYOBO, Osaka, Japan). The primers used for qRT-PCR are listed in Table S1. The

strains were inoculated on a blood plate at 37°C for 16–18 h. A single colony was selected and cultured in LB medium with shaking at 180 rpm until reaching the logarithmic phase at 37°C. The bacterial suspension was then harvested for RNA extraction by using the Trizol method. The PCR reaction was mixed well and microcentrifuged. Then, 10 µL of the mixture was transferred into the qPCR reaction plate, followed by qRT-PCR, as suggested by the manufacturer. The 16S rRNA gene was simultaneously used as a reference gene for data normalization, and the expression of each gene was determined by the $2^{-\Delta\Delta C_t}$ method. All experiments were performed in triplicate and repeated thrice independently.

Results

Antimicrobial Susceptibility Testing

Among the 2128 *E. faecalis* collected, 3.34% (71/2128) of *E. faecalis* isolates were resistant to the linezolid. Table 1 and Figure 1 show the MICs of linezolid, tedizolid, and radezolid against the linezolid-resistant isolates. Among the 71 linezolid-resistant isolates, the MICs of tedizolid and radezolid ranged from 1 to 4 µg/mL, and 0.5–1 µg/mL, respectively. The MIC₅₀/MIC₉₀ of tedizolid and radezolid exhibited 4- and 8-fold lower response than linezolid, respectively. This data suggests that in vitro activity of radezolid against 71 linezolid-resistant isolates was higher than tedizolid and linezolid.

Molecular Mechanisms of Linezolid-Resistant Isolates

Among the 71 linezolid-resistant *E. faecalis* clinical isolates, 57 isolates (80.28%) carried *optrA* only, 1 (1.41%) carried *cfr*, 4 (5.63%) carried both *optrA* and *cfr*, simultaneously, whereas the 6 (8.45%) isolates carried *optrA* and *cfr(D)*, simultaneously. Interestingly, *cfr(A)*, *cfr(C)*, and *potxA* genes were not detected in any of the isolates. Besides, no mutation for linezolid resistance was detected in the domain V of the 23S rRNA gene nor in the ribosomal proteins L3, L4, and L22. Detailed data of resistance mechanisms are provided in Table 1, Table S2 and Figure 1.

Transferability of Linezolid Resistance

The *optrA* and *cfr* genes were successfully transferred from 17.54% (10/57) *optrA*-positive isolates and 0% (0/1) *cfr*-positive to *E. faecalis* JH2-2, respectively. Furthermore, among four isolates carrying *optrA* and *cfr*

Table 1 MIC Ranges and the Rates of Positive Efflux Pump, Mutation, and Resistance Genes for Linezolid, Tedizolid, and Radezolid Against 71 Linezolid-Resistant *Enterococcus faecalis*

MIC Range (µg/mL)			Efflux Pump Positive rate (%)			Mutation Rate (%)					Resistance Genes Carrying Rate (%)						
LZD	TZD	RZD	LZD	TZD	RZD	P value	23S rRNA	rpIC	rpID	rpIV	optrA	cfr	cfr(A)	cfr(B)	cfr(C)	cfr(D)	potxA
8–16	1–4	0.5–1	0	5.63	100	P<0.05	0	0	0	0	94.37	7.04	0	0	0	8.75	0

Abbreviations: LZD, linezolid; TZD, tedizolid; RZD, radezolid.

Isolates	A MIC (μg/mL)			B Efflux pump				C Mutations				D Resistance genes							E Conjugation
	Linezolid	Tedizolid	Radezolid	Linezolid	Tedizolid	Radezolid		23S rRNA	rplC	rplD	rplV	optrA	cfr	Cfr(A)	Cfr(B)	Cfr(C)	Cfr(D)	potxA	
FC467	8	2	1																
FC496	8	1	1																
FC509	8	2	1																
FC511	8	2	1																
FC524	8	2	0.5																
FC696	16	2	1																
FC698	8	1	1																
FC700	8	1	1																
FC712	8	2	0.5																
FC725	8	2	1																
FC726	8	2	1																
FC752	8	2	1																
FC780	8	2	1																
FC832	8	2	1																
FC859	8	2	1																
FC902	8	2	1																
FC910	8	1	1																
FC969	8	2	1																
FC985	8	1	1																
FC1037	8	1	0.5																
FC1061	8	1	1																
FC1069	8	1	1																
FC1091	8	1	1																
FC1110	8	1	1																
FC1153	8	1	1																
FC1185	16	4	1																
FC-1260	8	1	1																
FC-1270	8	1	1																
FC-1285	8	1	1																
FC-1350	8	2	1																
FC-1354	8	2	1																
FC-1363	8	2	1																
FC-1368	8	1	1																
FC-1384	8	1	1																
FC-1387	8	1	1																
FC-1391	8	1	1																
FC-1409	8	2	1																
FC-1418	8	2	1																
FC-1428	8	1	1																
FC-1439	8	2	1																
FC-1466	8	2	1																
FC-1627	8	2	1																
FC-1728	8	2	0.5																
FC-1749	8	2	1																
FC-1784	8	2	1																
FC-1799	8	2	1																
FC-1805	8	2	1																
FC-1862	8	2	1																
FC-1868	8	2	1																
FC-1914	8	2	1																
FC-1964	8	2	1																
FC-1993	8	2	1																
FC-1996	8	2	1																
FC-2021	8	2	1																
FC-2041	8	2	1																
FC-2043	8	2	1																
FC-2050	8	2	1																
FC-2206	8	1	1																
FC-2234	8	1	1																
FC-2257	8	2	1																
FC-2279	8	2	1																
FC-2309	8	2	1																
FC-2311	8	2	1																
FC-2315	8	2	1																
FC-2339	8	2	1																
FC-2385	8	2	1																
FC-2398	8	2	1																
FC-2471	8	2	1																
FC-2484	8	1	1																
FC-2526	8	2	1																
FC-2559	8	2	1																

Figure 1 MIC ranges and the rates of positive efflux pump, mutation, and resistance genes for linezolid, tedizolid, and radezolid against 71 linezolid-resistance *Enterococcus faecalis* (A) MICs; (B) carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was used to detect the activity of efflux pumps; (C) the mutation of 23S rRNA and ribosomal proteins L3, L4, and L22; (D) the resistance genes of oxazolidinones; (E) the conjugation of resistance genes of oxazolidinones. Purple, Orange and blue squares represent positive, gray squares represent negative.

genes, one isolate transferred the *optrA* gene. Similarly, among six isolates carrying *optrA* and *cfr(D)* genes, one isolate successfully transferred the *optrA* gene. The

transfer rate of the *optrA*, *cfr*, and *cfr(D)* were 17.91% (12/67), 0% (0/5) and 0% (0/6), respectively (Figure 1).

Difference of Biofilm Formation Inhibition and Biofilm Clearance Ability of Three Antimicrobial Agents

The 8 linezolid-resistant *E. faecalis* clinical isolates (FC1996, FC2021, FC2234, FC2257, FC2279, FC2309, FC2471, and FC2484) were randomly selected for comparing the differential effects of linezolid, tedizolid and radezolid on *E. faecalis* biofilms. First, we compared the eradicating potential of linezolid, tedizolid, and radezolid (8 × MICs) on established *E. faecalis* biofilms. In most strains (FC1996, FC2234, FC2257, FC2279, FC2309, and FC2484), radezolid had a better clearance effect on biofilms than with linezolid and tedizolid, however, in 2 strains (FC2021 and FC2471) it was not statistically different. In general, for the biofilm clearance of linezolid-resistant strains of *E. faecalis*, radezolid has the best clearance effect, followed by linezolid, in most strains, tedizolid has a poor clearance effect on biofilm (Figure 2A). We also compared the biofilm formation inhibiting the ability of three antibiotics of oxazolidinone class in *E. faecalis* at the 1/4×MIC, 1/8×MIC, and 1/16×MIC. As shown in Figure 2B–D, most of the three antibacterial agents had a better inhibition effect on the formation of biofilm. Still, the inhibition effect varied as tedizolid at 1/4× or 1/8×MIC can efficiently inhibit the biofilm formation of *E. faecalis*, besides in most isolates, it had greater effect than linezolid and radezolid. This similar trend was also observed in several of the eight clinical isolates at MICs of 1/16×.

The Potential Effect of the Efflux Pump Mechanism

The correlation between efflux pump and three different generations of oxazolidinones against linezolid-resistant *E. faecalis* was tested. The results showed that after being exposed to efflux inhibitor CCCP (10 μg/mL), the MIC values of linezolid was in none of the strains decreased by 4-fold or more and the MICs of tedizolid decreased 4-fold only on 4 (5.63%) linezolid-resistant *E. faecalis*. Moreover, the MICs of radezolid on all linezolid-resistant isolates decreased ≥4-fold in combination with CCCP (10 μg/mL) (Tables 1, S3 and Figure 1). Among the three antimicrobial agents, the MICs of radezolid decreased most significantly, and the results showed that the effluent pump had the most significant

Figure 2 The effect of Linezolid, tedizolid, and radezolid to biofilms of *Enterococcus faecalis*. **(A)** The eradicated effect of Linezolid, tedizolid, and radezolid to established biofilms of *Enterococcus faecalis*. The 8 *E. faecalis* clinical isolates were allowed to form mature biofilms for 24 h, following which the established biofilms were treated with Linezolid, tedizolid, and radezolid (at 8 × their MICs for 48 h). The remaining biofilm biomass was determined by crystal violet staining. The inhibited effect of sub-minimum inhibitory concentrations (MICs) (1/4×MIC **(B)**, 1/8×MIC **(C)**, 1/16×MIC **(D)**) of linezolid, tedizolid and radezolid to *Enterococcus faecalis* biofilm formation. The 8 *E. faecalis* clinical isolates were treated with linezolid, tedizolid and radezolid at 1/4×their MICs for 24 h, and then biofilm biomass was determined by crystal violet staining. Data represent the average of three independent experiments (mean ± SD). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (Student's *t*-test).

effect on the MICs of radezolid ($p < 0.05$). Further, the results of RT-qPCR showed that these antibiotics (linezolid, tedizolid and radezolid) does not influence the expression of efflux pump gene (*OG1RF12220*, *OG1RF10126*, and *OG1RF10495*) (data not shown).

Discussion

With the extensive growing use of antimicrobial agents, MDR Gram-positive strains have also grown over some of last year's.²⁸ Linezolid has been extensively applied in clinical settings as a last-resort antimicrobial for treating the Gram-positive bacterial infections.³³ However, with the increasing clinical use of linezolid, the clinical practice has observed appearance of linezolid-resistant strains.³⁴ In this study, among the 2128 *E. faecalis* strains isolated from the First Affiliated Hospital of Wenzhou Medical University in 2011–2019, 3.34% (71/2128) of *E. faecalis*

were resistant to linezolid. Although our study showed that during a long period from 2011 to 2019, linezolid exhibited promising antimicrobial activity against clinically isolated *E. faecalis*, the resistance rate was low despite the emergence of the resistant strains. However, the emergence of resistant strains still was a great challenge, the new generation of oxazolidinone antibiotics development and application are urgent required. Our study further tested the antimicrobial activity of new oxazolidinone antibiotics tedizolid, and radezolid, against linezolid-resistant clinical *E. faecalis* isolates. The results showed that the MIC₅₀/MIC₉₀ of tedizolid and radezolid exhibited 4- and 8- fold lower than linezolid, respectively. Although tedizolid and radezolid are the new generations of oxazolidinone antibiotics, the antibacterial activity showed a different effect compared with linezolid. The results suggested that the in vitro activity of radezolid against

71 linezolid-resistant isolates was higher than that of tedizolid and linezolid. The differences between these three antibiotics are also worth further investigation in other aspects.

It is worth noting that the results of the gene carrying and mutation of oxazolidinone antimicrobial-resistant genes showed that 71 linezolid-resistant *E. faecalis* mainly had transferable gene *cfr*, *cfr(D)*, or *optrA*, and most strains carry *optrA*. This is consistent with previous reports. Thus, *OptrA* protein may play a significant role in mediating low-level linezolid resistance in *E. faecalis*.³⁵ This gene codes for an ATP-binding cassette (ABC) transporter that confers resistance to oxazolidinones.³⁶ Furthermore, *cfr* and its variant *cfr(D)* also decrease sensitivity to oxazolidinones.³⁷ Therefore, the presence of *optrA* and *cfr* is a concern because it may mediate multi-drug resistance. Of note, conjugation experiments with *E. faecalis* JH2-2 as recipients identified transferability of *optrA* gene between *E. faecalis*, which is consistent with the previous reports. Furthermore, there have been reports of easy transfer of *optrA*-carrying plasmids at high transfer frequencies of 10^{-2} – 10^{-6} in vitro between human- and pig-derived *E. faecalis*.³⁸ Although, in our study, 17.91% (12/67) *optrA* confers transferable resistance to oxazolidinones,³⁹ the presence of *optrA* may be in the plasmid or the chromosome in clinical isolates, which explain why the *optrA* in some strains cannot transfer.⁴⁰ Additionally, none of the linezolid-resistant isolates had mutation in L3, L4, or L22 ribosomal proteins which is associated with the prolonged courses of linezolid administration and also an important mutation mechanism for growing linezolid resistance.⁴¹

A biofilm is a structured community of microorganisms adhering to a surface and exhibiting recalcitrance to antimicrobial compounds and resisting human immune defenses' action.⁴² The production of *Enterococcus* biofilms is widespread in *Enterococcus faecalis*, and the worldwide incidence rate is 26–100%.⁴³ Studies have indicated that linezolid could affect the biofilms of *E. faecalis*.⁴⁴ Our research found that tedizolid had a significantly more significant inhibited effect on the biofilm formation of *E. faecalis*, which is higher than that of linezolid and radezolid. We further investigated whether this phenotypic was consistent with the eradication of established biofilms. Interestingly, we found that radezolid (at $8 \times$ their MIC) had the best scavenging effect on the established biofilms. Overall, the results show that the studied drugs in the biofilm inhibition have a significant difference, we speculated that the structure

and impact of different drugs made specific differences in their biofilm activity. On the other hand, biofilm formation was regulated by biofilm-regulated genes (*gelE*, *ace*, *esp*).⁴⁵ Different drugs may have different down-regulation abilities on these genes. In short, comparing different antimicrobial biofilm inhibition, exploring related to clinical biofilm formation strain of clear, and the treatment of skin tissue infections have a particular guiding value. More experiments and studies are needed to investigate in the future.

Oxazolidinone antibacterial agents, such as linezolid, show promising effects on Gram-positive bacteria, but show poor activity on Gram-negative bacteria such as *E. coli*, mainly due to the RND-type efflux pump AcrB has the intense action.⁴⁶ However, whether the efflux pump plays a role in the mechanism of Gram-positive bacteria resistant to linezolid, tedizolid or radezolid remains uncertain. In this study, the results indicated that among the three antimicrobial agents, the MICs of radezolid decreased most obviously after adding the addition of efflux pump inhibitor CCCP, followed by tedizolid. The efflux pump may be involved in the resistance to tedizolid and radezolid for *E. faecalis* isolates. However, we analyzed the effects of linezolid, tedizolid, and radezolid on the expression of efflux pump gene (*OG1RF12220*, *OG1RF10126*, and *OG1RF1049*) referring to Zheng et al,²⁶ our results showed it did not influence these efflux pumps. The role of other efflux pump would also be studied in our future studies. The application of transcriptome sequencing will also be necessary to determine which efflux pump gene is active and to elucidate the specific mechanism in the future studies. In a word, the differences in the effect of efflux pumps of tedizolid, radezolid, and linezolid against linezolid-resistant isolates still need to be further investigated in the future.

In conclusion, the majority of *E. faecalis* isolates in our study were highly susceptible to linezolid. At the same time, both tedizolid and radezolid, the new generation of antimicrobial agents, showed different antibacterial activity to linezolid-resistant *E. faecalis*. The in vitro activity of radezolid against 71 linezolid-resistant isolates was higher than that of tedizolid and linezolid. Transferable genes *cfr*, *cfr(D)*, and *optrA* may be involved in developing antimicrobial resistance to oxazolidinones of *E. faecalis* in this study. We also showed that radezolid was more effective in eradication biofilm, and tedizolid showed more effectiveness in inhibiting biofilm formation. Additionally, the efflux pump inhibition test results

showed that the effluent pump had the most significant effect on the MICs of radezolid, but it is still essential to explore the mechanism of further study in the future. In a word, comparing the anti-microbic and anti-biofilm activity of three different oxazolidinone antibiotics can better understand them and guide clinical drug use may provide guiding value for clinical medication and treatment.

Ethical Approval

Whole investigation protocols in this study were approved by The Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University.

Acknowledgments

We sincerely thank all the medical workers of the Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University for cooperating this study.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, agreed to the submitted journal, and agreed to be accountable for all aspects of the work.

Disclosure

Lingbo Wang and Ying Zhang are co-first authors for this study. The authors report no conflicts of interest in this work.

References

- Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of enterococci. *Microbiol Spectr*. 2019;7. doi:10.1128/microbiolspec.GPP3-0053-2018
- Kline KA, Lewis AL. Gram-positive uropathogens, polymicrobial urinary tract infection, and the emerging microbiota of the urinary tract. *Microbiol Spectr*. 2016;4. doi:10.1128/microbiolspec.UTI-0012-2012
- Beganovic M, Luther MK, Rice LB, et al. A review of combination antimicrobial therapy for *Enterococcus faecalis* bloodstream infections and infective endocarditis. *Clin Infect Dis*. 2018;67:303–309. doi:10.1093/cid/ciy064
- Gilmore MS, Salamzade R, Selleck E, et al. Genes contributing to the unique biology and intrinsic antibiotic resistance of *Enterococcus faecalis*. *mBio*. 2020;11. doi:10.1128/mBio.02962-20
- Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. *Antimicrob Agents Chemother*. 1996;40:839–845. doi:10.1128/AAC.40.4.839
- Ippolito JA, Kanyo ZF, Wang D, et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. *J Med Chem*. 2008;51:3353–3356. doi:10.1021/jm800379d
- Aoki H, Ke L, Poppe SM, et al. Oxazolidinone antibiotics target the P site on *Escherichia coli* ribosomes. *Antimicrob Agents Chemother*. 2002;46:1080–1085. doi:10.1128/aac.46.4.1080-1085.2002
- Wang J, Xia L, Wang R, et al. Linezolid and its immunomodulatory effect: in vitro and in vivo evidence. *Front Pharmacol*. 2019;10:1389. doi:10.3389/fphar.2019.01389
- Liu BG, Yuan XL, He DD, et al. Research progress on the oxazolidinone drug linezolid resistance. *Eur Rev Med Pharmacol Sci*. 2020;24:9274–9281. doi:10.26355/eurrev_202009_23009
- Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. *Clin Infect Dis*. 2015;61:1315–1321. doi:10.1093/cid/civ501
- Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. *Antimicrob Agents Chemother*. 2008;52:4442–4447. doi:10.1128/AAC.00859-08
- Jiang J, Hou Y, Duan M, et al. Design, synthesis and antibacterial evaluation of novel oxazolidinone derivatives nitrogen-containing fused heterocyclic moiety. *Bioorg Med Chem Lett*. 2021;32:127660. doi:10.1016/j.bmcl.2020.127660
- Bassetti M, Righi E. Safety profiles of old and new antimicrobials for the treatment of MRSA infections. *Expert Opin Drug Saf*. 2016;15:467–481. doi:10.1517/14740338.2016.1142528
- Carvalhaes CG, Sader HS, Flamm RK, et al. Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018. *Antimicrob Agents Chemother*. 2020;64. doi:10.1128/AAC.00175-20
- Torres C, Alonso CA, Ruiz-Ripa L, et al. Antimicrobial resistance in *Enterococcus* spp. of animal origin. *Microbiol Spectr*. 2018;6. doi:10.1128/microbiolspec.ARBA-0032-2018
- Deshpande LM, Castanheira M, Flamm RK, et al. Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. *J Antimicrob Chemother*. 2018;73:2314–2322. doi:10.1093/jac/dky188
- Moure Z, Lara N, Marin M, et al. Interregional spread in Spain of linezolid-resistant *Enterococcus* spp. isolates carrying the *optrA* and *poxtA* genes. *Int J Antimicrob Agents*. 2020;55:105977. doi:10.1016/j.ijantimicag.2020.105977
- Li P, Yang Y, Ding L, et al. Molecular investigations of linezolid resistance in enterococci *Optra* variants from a hospital in Shanghai. *Infect Drug Resist*. 2020;13:2711–2716. doi:10.2147/IDR.S251490
- Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. *Expert Rev Anti Infect Ther*. 2014;12:1221–1236. doi:10.1586/14787210.2014.956092
- Klupp EM, Both A, Belmar Campos C, et al. Tedizolid susceptibility in linezolid- and vancomycin-resistant *Enterococcus faecium* isolates. *Eur J Clin Microbiol Infect Dis*. 2016;35:1957–1961. doi:10.1007/s10096-016-2747-0
- Bai B, Hu K, Li H, et al. Effect of tedizolid on clinical *Enterococcus* isolates: in vitro activity, distribution of virulence factor, resistance genes and multilocus sequence typing. *FEMS Microbiol Lett*. 2018;365. doi:10.1093/femsle/fnx284
- Xu Z, Wei Y, Wang Y, et al. In vitro activity of radezolid against *Enterococcus faecium* and compared with linezolid. *J Antibiot (Tokyo)*. 2020;73:845–851. doi:10.1038/s41429-020-0345-y
- Lewis K. Riddle of biofilm resistance. *Antimicrob Agents Chemother*. 2001;45:999–1007. doi:10.1128/AAC.45.4.999-1007.2001
- Bayston R, Ullas G, Ashraf W. Action of linezolid or vancomycin on biofilms in ventriculoperitoneal shunts in vitro. *Antimicrob Agents Chemother*. 2012;56:2842–2845. doi:10.1128/AAC.06326-11

25. Holmberg A, Morgelin M, Rasmussen M. Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against *Enterococcus faecalis* in biofilms. *J Antimicrob Chemother.* 2012;67:433–439. doi:10.1093/jac/dkr477
26. Zheng J, Chen Z, Lin Z, et al. Radezolid is more effective than linezolid against planktonic cells and inhibits *Enterococcus faecalis* Biofilm Formation. *Front Microbiol.* 2020;11:196. doi:10.3389/fmicb.2020.00196
27. Performance CLSI. *Standards for Antimicrobial Susceptibility Testing.* 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
28. Patel SN, Memari N, Shahinas D, et al. Linezolid resistance in *Enterococcus faecium* isolated in Ontario, Canada. *Diagn Microbiol Infect Dis.* 2013;77:350–353. doi:10.1016/j.diagmicrobio.2013.08.012
29. Ruiz-Ripa L, Fessler AT, Hanke D, et al. Mechanisms of linezolid resistance among enterococci of clinical origin in Spain-detection of *optrA*- and *cfr(D)*-carrying *E. faecalis*. *Microorganisms.* 2020;8:1155. doi:10.3390/microorganisms8081155
30. Huys G, D'Haene K, Collard JM, et al. Prevalence and molecular characterization of tetracycline resistance in *Enterococcus* isolates from food. *Appl Environ Microbiol.* 2004;70:1555–1562. doi:10.1128/aem.70.3.1555-1562.2004
31. Zheng JX, Sun X, Lin ZW, et al. In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of *Enterococcus faecalis*. *J Med Microbiol.* 2019;68:493–502. doi:10.1099/jmm.0.000945
32. Mlynec KD, Callahan MT, Shimkevitch AV, et al. Effects of low-dose amoxicillin on *Staphylococcus aureus* USA300 Biofilms. *Antimicrob Agents Chemother.* 2016;60:2639–2651. doi:10.1128/AAC.02070-15
33. Koulenti D, Xu E, Song A, et al. Emerging treatment options for infections by multidrug-resistant gram-positive microorganisms. *Microorganisms.* 2020;8:191. doi:10.3390/microorganisms8020191
34. Bai B, Hu K, Zeng J, et al. Linezolid consumption facilitates the development of linezolid resistance in *Enterococcus faecalis* in a tertiary-care hospital: a 5-Year Surveillance Study. *Microb Drug Resist.* 2019;25:791–798. doi:10.1089/mdr.2018.0005
35. Yan J, Xia Y, Yang M, et al. Quantitative proteomics analysis of membrane proteins in *Enterococcus faecalis* with low-level linezolid-resistance. *Front Microbiol.* 2018;9:1698. doi:10.3389/fmicb.2018.01698
36. Cai J, Wang Y, Schwarz S, et al. Enterococcal isolates carrying the novel oxazolidinone resistance gene *optrA* from hospitals in Zhejiang, Guangdong, and Henan, China, 2010–2014. *Clin Microbiol Infect.* 2015;21:1095e1–4. doi:10.1016/j.cmi.2015.08.007
37. Guerin F, Sassi M, Dejoies L, et al. Molecular and functional analysis of the novel *cfr(D)* linezolid resistance gene identified in *Enterococcus faecium*. *J Antimicrob Chemother.* 2020;75:1699–1703. doi:10.1093/jac/dkaa125
38. Shang Y, Li D, Shan X, et al. Analysis of two pheromone-responsive conjugative multiresistance plasmids carrying the novel mobile *optrA* locus from *Enterococcus faecalis*. *Infect Drug Resist.* 2019;12:2355–2362. doi:10.2147/IDR.S206295
39. Wang Y, Lv Y, Cai J, et al. A novel gene, *optrA*, that confers transferable resistance to oxazolidinones and phenicols and its presence in *Enterococcus faecalis* and *Enterococcus faecium* of human and animal origin. *J Antimicrob Chemother.* 2015;70:2182–2190. doi:10.1093/jac/dkv116
40. Zou J, Tang Z, Yan J, et al. Dissemination of linezolid resistance through sex pheromone plasmid transfer in *Enterococcus faecalis*. *Front Microbiol.* 2020;11:1185. doi:10.3389/fmicb.2020.01185
41. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant *Enterococcus faecium* resistant to linezolid. *Lancet.* 2001;357:1179. doi:10.1016/S0140-6736(00)04376-2
42. Nostro A, Roccaro AS, Bisignano G, et al. Effects of oregano, carvacrol and thymol on *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. *J Med Microbiol.* 2007;56:519–523. doi:10.1099/jmm.0.46804-0
43. Tong J, Jiang Y, Xu H, et al. In vitro antimicrobial activity of fosfomycin, rifampin, vancomycin, daptomycin alone and in combination against vancomycin-resistant enterococci. *Drug Des Devel Ther.* 2021;15:3049–3055. doi:10.2147/DDDT.S315061
44. Luther MK, Arvanitis M, Mylonakis E, et al. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming *Enterococcus faecalis* or *E. faecium* in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using *Galleria mellonella* larvae. *Antimicrob Agents Chemother.* 2014;58:4612–4620. doi:10.1128/AAC.02790-13
45. Xiao B, Zou Z, Bhandari J, et al. Exposure to diode laser (810nm) affects the bacterial adherence and biofilm formation in a *E. faecalis* biofilm model. *Photodiagnosis Photodyn Ther.* 2020;31:101772. doi:10.1016/j.pdpdt.2020.101772
46. Schumacher A, Trittler R, Bohnert JA, et al. Intracellular accumulation of linezolid in *Escherichia coli*, *Citrobacter freundii* and *Enterobacter aerogenes*: role of enhanced efflux pump activity and inactivation. *J Antimicrob Chemother.* 2007;59:1261–1264. doi:10.1093/jac/dkl380

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress